Comparison
BPC-157 vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Healing
CAS no.
137525-51-0
no data
Molecular weight
1419.5 g/mol
888 g/mol
Half-life
4 h
no data
Sequence
GEPPPGKPADDAGLVAc-LKKTETQMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Animal model
Animal model
Studies
4
3
of which in humans
0
0
Effects recorded
4
4
Open conflicts
2
1
Documented adverse events
2
2